{"filing":{"accession_number":"0001104659-26-075130","cik":"0001157601","ticker":"MDGL","company_name":"MADRIGAL PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"tm2617490d2_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1157601/000110465926075130/tm2617490d2_8k.htm"},"events":[{"id":11546,"run_id":10141,"accession_number":"0001104659-26-075130","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Madrigal Pharmaceuticals held its Annual Meeting of Stockholders on June 17, 2026, with shareholders voting on five matters: re-election of three Class I directors, advisory vote on named executive officer compensation, ratification of PricewaterhouseCoopers LLP as independent auditor, approval of the 2026 Stock Plan, and approval of the 2026 Employee Stock Purchase Plan. The filing discloses complete voting tallies (For, Against, Abstentions, Broker Non-Votes) for each matter.","company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8154,"accession_number":"0001104659-26-075130","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Madrigal Pharmaceuticals' Annual Meeting held on June 17, 2026, covering five matters: re-election of three Class I directors, advisory vote on named executive officer compensation, ratification of PricewaterhouseCoopers LLP as independent auditor, approval of the 2026 Stock Plan, and approval of the 2026 ESPP. The filing presents voting tallies (For, Against, Abstentions, Broker Non-Votes) for each matter, which is the hallmark of Item 5.07 shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:09:14.459288+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":11547,"run_id":10141,"accession_number":"0001104659-26-075130","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The Board adopted a Nonqualified Deferred Compensation Plan for named executive officers and directors, and entered into a consulting agreement with Dr. Rebecca Taub (Class II director) providing $100,000 annually plus director compensation. These compensatory arrangements were approved by stockholders as part of the Annual Meeting voting on the 2026 Stock Plan and 2026 Employee Stock Purchase Plan.","company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8153,"accession_number":"0001104659-26-075130","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses multiple compensatory arrangements: stockholder approval of the 2026 Stock Plan and 2026 Employee Stock Purchase Plan, Board adoption of a Nonqualified Deferred Compensation Plan for named executive officers and directors, and a consulting agreement with Dr. Rebecca Taub (a Class II director) providing $100,000 annually plus director compensation. These are material executive compensation disclosures under Item 5.02(e), though the section also touches on Dr. Taub's transition from employee to consultant status.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:09:14.459288+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8153,"accession_number":"0001104659-26-075130","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses multiple compensatory arrangements: stockholder approval of the 2026 Stock Plan and 2026 Employee Stock Purchase Plan, Board adoption of a Nonqualified Deferred Compensation Plan for named executive officers and directors, and a consulting agreement with Dr. Rebecca Taub (a Class II director) providing $100,000 annually plus director compensation. These are material executive compensation disclosures under Item 5.02(e), though the section also touches on Dr. Taub's transition from employee to consultant status.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:09:14.459288+00:00","company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","filing_date":"2026-06-17"},{"id":8154,"accession_number":"0001104659-26-075130","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Madrigal Pharmaceuticals' Annual Meeting held on June 17, 2026, covering five matters: re-election of three Class I directors, advisory vote on named executive officer compensation, ratification of PricewaterhouseCoopers LLP as independent auditor, approval of the 2026 Stock Plan, and approval of the 2026 ESPP. The filing presents voting tallies (For, Against, Abstentions, Broker Non-Votes) for each matter, which is the hallmark of Item 5.07 shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:09:14.459288+00:00","company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","filing_date":"2026-06-17"}]}